Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Systemic Lupus Erythematosus and Pulmonary Arterial Hypertension: Evidence From Transcriptome Data

被引:47
作者
Yao, Menghui [1 ]
Zhang, Chunyi [1 ]
Gao, Congcong [1 ]
Wang, Qianqian [1 ]
Dai, Mengmeng [1 ]
Yue, Runzhi [1 ]
Sun, Wenbo [1 ]
Liang, Wenfang [1 ]
Zheng, Zhaohui [1 ]
机构
[1] Zhengzhou Univ, Dept Rheumatol, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
systemic lupus erythematosus; pulmonary arterial hypertension; WGCNA; differential gene analysis; type I IFN; miRNAs-mRNAs; I INTERFERON; RISK-FACTORS; UBIQUITIN; CELLS; MANIFESTATIONS; PATHOGENESIS; SURVIVAL; IMMUNITY; DISEASE;
D O I
10.3389/fimmu.2021.658341
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect multiple systems. Pulmonary arterial hypertension (PAH) has a close linkage with SLE. However, the inter-relational mechanisms between them are still unclear. This article aimed to explore the shared gene signatures and potential molecular mechanisms in SLE and PAH. Methods The microarray data of SLE and PAH in the Gene Expression Omnibus (GEO) database were downloaded. The Weighted Gene Co-Expression Network Analysis (WGCNA) was used to identify the co-expression modules related to SLE and PAH. The shared genes existing in the SLE and PAH were performed an enrichment analysis by ClueGO software, and their unique genes were also performed with biological processes analyses using the DAVID website. The results were validated in another cohort by differential gene analysis. Moreover, the common microRNAs (miRNAs) in SLE and PAH were obtained from the Human microRNA Disease Database (HMDD) and the target genes of whom were predicted through the miRTarbase. Finally, we constructed the common miRNAs-mRNAs network with the overlapped genes in target and shared genes. Results Using WGCNA, four modules and one module were identified as the significant modules with SLE and PAH, respectively. A ClueGO enrichment analysis of shared genes reported that highly activated type I IFN response was a common feature in the pathophysiology of SLE and PAH. The results of differential analysis in another cohort were extremely similar to them. We also proposed a disease road model for the possible mechanism of PAH secondary to SLE according to the shared and unique gene signatures in SLE and PAH. The miRNA-mRNA network showed that hsa-miR-146a might regulate the shared IFN-induced genes, which might play an important role in PAH secondary to SLE. Conclusion Our work firstly revealed the high IFN response in SLE patients might be a crucial susceptible factor for PAH and identified novel gene candidates that could be used as biomarkers or potential therapeutic targets.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Ischemic Stroke and Atherosclerosis
    Ban, Ru
    Huo, Chengju
    Wang, Jingru
    Zhang, Guifeng
    Zhao, Xin
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 2223 - 2239
  • [32] Circulating extracellular vesicles as novel biomarkers for pulmonary arterial hypertension in patients with systemic lupus erythematosus
    Ding, Zhe
    Qi, Fumin
    Liu, Li
    Wang, Zhouming
    Zhang, Na
    Lyu, Xing
    Sun, Wenwen
    Du, Jun
    Song, Haoming
    Hou, Hou
    Guo, Ying
    Wang, Xiaomei
    Liu, Ming-Lin
    Wei, Wei
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [33] Arterial stiffness, antiphospholipid antibodies, and pulmonary arterial hypertension in systemic lupus erythematosus
    Lee, Ji Hyun
    Cho, Kyoung Im
    JOURNAL OF CARDIOLOGY, 2014, 64 (5-6) : 450 - 455
  • [34] Identification of the shared gene signatures between pulmonary fibrosis and pulmonary hypertension using bioinformatics analysis
    Zhao, Hui
    Wang, Lan
    Yan, Yi
    Zhao, Qin-Hua
    He, Jing
    Jiang, Rong
    Luo, Ci-Jun
    Qiu, Hong-Ling
    Miao, Yu-Qing
    Gong, Su-Gang
    Yuan, Ping
    Wu, Wen-Hui
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [35] Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors
    Zhang, Na
    Li, Mengtao
    Qian, Junyan
    Wang, Qian
    Zhao, Jiuliang
    Yang, Zhenwen
    Tian, Zhuang
    Zhang, Xiao
    Zuo, Xiaoxia
    Zhang, Miaojia
    Zhu, Ping
    Ye, Shuang
    Zhang, Wei
    Zheng, Yi
    Qi, Wufang
    Li, Yang
    Zhang, Zhuoli
    Ding, Feng
    Gu, Jieruo
    Liu, Yi
    Wei, Wei
    Zeng, Xiaofeng
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (05) : 921 - 928
  • [36] Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension
    Mok, M. Y.
    Tsang, P. L.
    Lam, Y. M.
    Lo, Y.
    Wong, W. S.
    Lau, C. S.
    LUPUS, 2007, 16 (04) : 279 - 285
  • [37] Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report
    Hennigan, S.
    Channick, R. N.
    Silverman, G. J.
    LUPUS, 2008, 17 (08) : 754 - 756
  • [38] Successful pregnancy in pulmonary arterial hypertension associated with systemic lupus erythematosus: A case report
    Streit M.
    Speich R.
    Fischler M.
    Ulrich S.
    Journal of Medical Case Reports, 3 (1)
  • [39] Exploration of shared gene signatures and molecular mechanisms between type 2 diabetes and osteoporosis
    Du, Ashuai
    Xu, Rong
    Yang, Qinglong
    Lu, Yingxue
    Luo, Xinhua
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (09)
  • [40] PULMONARY ARTERIAL-HYPERTENSION RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    MORELLI, S
    GIORDANO, M
    DEMARZIO, P
    PRIORI, R
    SGRECCIA, A
    VALESINI, G
    LUPUS, 1993, 2 (06) : 367 - 369